focus -WSS

focus

author：explore 2025-09-30 00:37:33 - browse：6

Exact Sciences headquarters. -- biotech coverage from STAT — Exact Sciences' headquarters in Madison, Wis. Wikimedia Commons

Exact Sciences reported first-quarter revenues this week that beat market expectations, and the cancer detection company’s executives still believe they’re on track to meet expected 2024 revenue.

That’s usually good news. Yet Exact shares are down nearly 11% on Thursday, dipping to $53.12 within the first few hours of trading. During after-hours trading on Wednesday, shortly after Exact released its financial updates, shares tumbled as low as $47.24.

The seemingly paradoxical result reflects worries about a potential slowdown in future growth at Exact, a $10 billion biotech best known for Cologuard, a colon cancer screening test that detects blood and DNA from stool samples. The test, which first won regulatory approval in 2014, was designed to boost cancer screening rates by providing a more convenient alternative to colonoscopies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

WSS

Boston competes with Raleigh

Pancreatic cancer early detection could be helped by AI

Congress must reauthorize a committee to support older Americans

Merck, Johnson & Johnson CEOs will testify on high drug prices

Poor hospice wound care hurts patients and families

Syphilis numbers in the United States reach record heights

entertainment

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Drug repurposing or repositioning? The language matters

FTC sues over Novant Health acquisition of two N.C. hospitals

Medicare details structure of new drug price negotiation program

White House pharmacy plagued with problems, investigation finds

How to save PrEP access — and even expand it

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

NYU radiologists take on the challenge of expensive MRI machines

Walensky prepares to leave CDC — and Congress — behind

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

focus

Zyn nicotine pouches become unlikely player in latest culture war

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Why you shouldn’t ask, “What country has the best health care?”

World's first CRISPR

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Astellas still sees hope in its gene therapy after four deaths

hotspot

focus

leisure time

focus